ClinicalTrials.gg
TerminatedNCT04193293Updated Sep 21, 2023Results posted

A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer

A Phase 1/2 interventional study of Duvelisib and Pembrolizumab in Head and Neck Squamous Cell Carcinoma, sponsored by SecuraBio. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-21.

Sponsored by SecuraBio · Phase 1/2, Interventional, and Treatment

Why this study was terminated
The study was terminated due to low enrollment.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
2
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States — 217 open to participants now, 347 under way, 28 of them phase 3. Squamous Cell Carcinoma of Head and Neck · United States.

Enrollment
938th of 993
2 · median 41
Started
2020
with 69 others
Phase 1/2
157 of 1,099
42 open now
Registered
655th of 1,099
by date

Among the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, this one is the 938th largest by enrollment of the 993 interventional ones that give a count, is one of 70 that started in 2020, is one of 157 in phase 1/2, and was the 655th registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

217 of the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States are open now. Recruiting first, the newest first:

212 more — sign in →

All 217 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, or all of them as a file.
02

Study summary

This study was designed to assess the safety and preliminary efficacy of duvelisib in combination with pembrolizumab in participants with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

Read the detailed description

This was a non-randomized, open-label Phase 1b/2 study designed to evaluate safety, tolerability, and preliminary efficacy of duvelisib in combination with pembrolizumab in participants with R/M HNSCC who were eligible for pembrolizumab monotherapy based on the current pembrolizumab prescribing information.

03

Conditions studied

  • Head and Neck Squamous Cell Carcinoma

Keywords

  • Squamous Cell Carcinoma of the Head and Neck
  • Head and Neck Cancer
  • PI3K-δ,γ
  • PI3K Inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • performance status ≤ 1
  • or cytologically confirmed diagnosis of recurrent or head and neck squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx that was considered incurable by local therapies
  • Eligible for pembrolizumab monotherapy based on the current prescribing information for pembrolizumab (Keytruda 2019)
  • Must have had 0 to 2 prior therapies for R/M HNSCC
  • At least 1 (which has not been previously irradiated) according to version 1.1
  • For stage 1 only: Must have had at least 1 other lesion that could be biopsied and willing to undergo a pretreatment and on-treatment of the available tumor lesion
  • For stage 1 only: Must have been willing to undergo a pretreatment and on-treatment biopsy of the available tumor lesion
  • Adequate organ function defined by the following laboratory parameters:

    • ≥ 1.5 × 10\^9/liter (L)
    • count ≥ 100 × 10\^9/L
    • level ≥ 9.0 grams/deciliter (dL)
    • A serum creatinine level \< 1.5 milligrams/dL, or
    • Estimated value ≥ 60 milliliters/minute (as determined by the Cockcroft-Gault method) for participants with creatinine levels > 1.5 × institutional (ULN)
    • Total level ≤ 1.5 × ULN (exception: participants with Gilbert's Syndrome may have a bilirubin level > 1.5 × ULN)
    • /serum glutamic-oxaloacetic transaminase and alanine aminotransferase/serum pyruvic transaminase levels ≤ 2.5 × ULN or ≤ 5 × ULN in participants with liver metastases
  • or prothrombin time (PT) and activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN, unless participant was receiving anticoagulant therapy in which case PT or aPTT must have been within therapeutic range of intended use of anticoagulants

Exclusion criteria

Exclusion Criteria

  • Previously treated with 3 or more systemic regimens given for recurrent and/or disease
  • Received anticancer treatment, major surgery, or any drug within 30 days or 5 half-lives, whichever is shorter, before the start of study intervention
  • Received radiation therapy within 14 days before the start of study intervention, including, in addition (if necessary), the timeframe for resolution of any actual or anticipated toxicities from such radiation; Palliative radiation is allowed if > 7 days and any toxicity is ≤ Grade 1
  • Previous treatment with a PI3K, or programmed cell death ligand 1 inhibitor
  • Have received organ or allogenic bone marrow or peripheral blood stem cell transplant
  • History of drug-induced colitis or drug-induced pneumonitis; history or concurrent condition of interstitial lung disease of any severity and/or severely impaired lung function; tuberculosis treatment within 2 years prior to the start of study intervention; chronic liver disease or veno-occlusive disease/sinusoidal obstruction syndrome
  • Active cytomegalovirus or Epstein-Barr virus infection; history of or known infection
  • Ongoing treatment with chronic or systemic or treatment for systemic bacterial, fungal, or viral infection
  • Unable to receive prophylactic treatment for pneumocystis, herpes simplex virus (HSV), or herpes zoster (VZV) at screening
  • Concurrent administration of medications or foods that are strong inhibitors or inducers of cytochrome P450 3A. No prior use within 2 weeks before the start of study intervention Received a live or within 6 weeks of first dose of duvelisib
  • Unable to receive prophylactic treatment for pneumocystis, HSV, or VZV at screening
  • Any active gastrointestinal dysfunction interfering with the participant's ability to be administered oral medications
  • Known active central nervous system metastases and/or carcinomatous meningitis
  • > 500 milliseconds (except for participants with a right or left bundle branch block)
  • Class III or IV congestive heart failure
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    Duvelisib + Pembrolizumab

    Stage 1: Duvelisib twice daily (BID) for 1 week followed by combination therapy with duvelisib BID + pembrolizumab every 3 weeks (q3w) (Cycle 1 was 4 weeks consisting of the 1-week duvelisib monotherapy lead-in period followed by 1 dose of pembrolizumab in combination with 3 additional weeks of continuous dosing of duvelisib; subsequent cycles were 3 weeks). Stage 2: Duvelisib BID + pembrolizumab q3w in 3-week cycles.

    Drug: Duvelisib · Biological: Pembrolizumab

Interventions

  • Phosphoinositide 3-kinase (PI3K) Inhibitor

    Also known as: VS-0145, Copiktra

  • BiologicalPembrolizumab

    Immunotherapy (programmed cell death protein 1 \[PD-1\] inhibitor)

    Also known as: PD-1 inhibitor, anti-PD-1, Keytruda

06

What researchers measure

Primary outcomes

  1. Stage 1: Number of Participants With Dose-limiting Toxicities

    Time frame: 4 weeks or 28 days

  2. Stage 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Number of participants with TEAEs as assessed by the Common Terminology Criteria for Adverse Events version 5 (CTCAE v5) as a measure of safety and tolerability of duvelisib in combination with pembrolizumab.

    Time frame: 6 months

  3. Stage 1 and 2: Overall Response Rate (ORR)

    Proportion of participants achieving complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1).

    Time frame: Up to 2 years

Secondary outcomes

  1. Stage 1: ORR

    Proportion of participants achieving complete CR or PR according to RECIST v 1.1.

    Time frame: Until documented progressive disease (PD), unacceptable toxicity, discontinuation criteria are met, withdrawal, or death (up to 2 years)

  2. Stage 1 and 2: Duration of Response (DOR)

    Time from response ≥ PR to documented disease progression according to RECIST v 1.1.

    Time frame: From first response until documented PD (up to 2 years)

  3. Stage 1 and 2: Progression-free Survival (PFS)

    Time from start of treatment to documented disease progression according to RECIST v 1.1, or death due to any cause.

    Time frame: From start of treatment until documented PD or death (up to 2.5 years)

  4. Stage 1 and 2: Overall Survival

    Time from start of treatment to death.

    Time frame: From start of treatment until death (up to 2.5 years)

  5. Stage 1 and 2: Maximum Observed Concentration [Cmax]

    Pharmacokinetics (PK) parameters for duvelisib (and metabolite IPI-656) determined using bioanalytical data and Population PK (POPPK) modeling.

    Time frame: Up to 5 cycles (46 weeks)

  6. Stage 1 and 2: Area Under the Curve [AUC]

    PK parameters for duvelisib (and metabolite IPI-656) determined using bioanalytical data and POPPK modeling.

    Time frame: Up to 5 cycles (46 weeks)

  7. Stage 1 and 2: Number of Participants With TEAEs

    Number of participants with TEAEs as assessed by CTCAE v5.0.

    Time frame: 24 months

07

Results

Posted Apr 7, 2023
Limitations and caveats
The study was terminated early by the Sponsor due to low enrollment. Due to study termination and only 2 participants receiving treatment, there are concerns regarding participant confidentiality, therefore no data are being reported.

Participant flow

Participant flow — Overall Study
MilestoneDuvelisib + Pembrolizumab
Started0
Completed0
Not completed0

Outcome measures

PrimaryStage 1: Number of Participants With Dose-limiting Toxicities
Time frame:
4 weeks or 28 days

No measurements were reported for this outcome.

PrimaryStage 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

Number of participants with TEAEs as assessed by the Common Terminology Criteria for Adverse Events version 5 (CTCAE v5) as a measure of safety and tolerability of duvelisib in combination with pembrolizumab.

Time frame:
6 months

No measurements were reported for this outcome.

PrimaryStage 1 and 2: Overall Response Rate (ORR)

Proportion of participants achieving complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1).

Time frame:
Up to 2 years

No measurements were reported for this outcome.

SecondaryStage 1: ORR

Proportion of participants achieving complete CR or PR according to RECIST v 1.1.

Time frame:
Until documented progressive disease (PD), unacceptable toxicity, discontinuation criteria are met, withdrawal, or death (up to 2 years)

No measurements were reported for this outcome.

SecondaryStage 1 and 2: Duration of Response (DOR)

Time from response ≥ PR to documented disease progression according to RECIST v 1.1.

Time frame:
From first response until documented PD (up to 2 years)

No measurements were reported for this outcome.

SecondaryStage 1 and 2: Progression-free Survival (PFS)

Time from start of treatment to documented disease progression according to RECIST v 1.1, or death due to any cause.

Time frame:
From start of treatment until documented PD or death (up to 2.5 years)

No measurements were reported for this outcome.

SecondaryStage 1 and 2: Overall Survival

Time from start of treatment to death.

Time frame:
From start of treatment until death (up to 2.5 years)

No measurements were reported for this outcome.

SecondaryStage 1 and 2: Maximum Observed Concentration [Cmax]

Pharmacokinetics (PK) parameters for duvelisib (and metabolite IPI-656) determined using bioanalytical data and Population PK (POPPK) modeling.

Time frame:
Up to 5 cycles (46 weeks)

No measurements were reported for this outcome.

SecondaryStage 1 and 2: Area Under the Curve [AUC]

PK parameters for duvelisib (and metabolite IPI-656) determined using bioanalytical data and POPPK modeling.

Time frame:
Up to 5 cycles (46 weeks)

No measurements were reported for this outcome.

SecondaryStage 1 and 2: Number of Participants With TEAEs

Number of participants with TEAEs as assessed by CTCAE v5.0.

Time frame:
24 months

No measurements were reported for this outcome.

Adverse events

Collected over This study was terminated by the Sponsor. Due to study termination and only 2 participants receiving treatment, there are concerns regarding participant confidentiality, therefore no data are being reported.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Duvelisib + Pembrolizumab———

Baseline characteristics

This study was terminated by the Sponsor. Due to study termination and only 2 participants receiving treatment, there are concerns regarding participant confidentiality, therefore no data are being reported.

Age, Continuous
Age, ContinuousDuvelisib + Pembrolizumab
Sex: Female, Male
Sex: Female, MaleDuvelisib + Pembrolizumab
Female—
Male—
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)Duvelisib + Pembrolizumab
Hispanic or Latino—
Not Hispanic or Latino—
Unknown or Not Reported—
Race (NIH/OMB)
Race (NIH/OMB)Duvelisib + Pembrolizumab
American Indian or Alaska Native—
Asian—
Native Hawaiian or Other Pacific Islander—
Black or African American—
White—
More than one race—
Unknown or Not Reported—
08

Study locations

1 site
  • UPMC Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2020 to primary completion in Dec 2020, 6 months.

Results were first posted in Apr 2023, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2019
First posted
Dec 10, 2019
StartActual
Jun 1, 2020
Primary completionActual
Dec 10, 2020
CompletionActual
Dec 10, 2020
Results first posted
Apr 7, 2023
Last update
Sep 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04193293
Lead sponsor
SecuraBio
Responsible party
Sponsor
First posted
Dec 10, 2019
Start date
Jun 1, 2020
Primary completion
Dec 10, 2020
Completion
Dec 10, 2020
Results posted
Apr 7, 2023
Last update
Sep 21, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Duvelisib

Start the discussion